Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
Authors' conclusion
In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.
Study context
- Population
- Patients with RA/SSc overlap syndrome treated with targeted therapies, two academic centres
- Participants
- 4 / 5 / 8 / 4
- Exposure
- T and B lymphocyte-targeted therapies vs cytokine inhibitors
- Abataceptn = 4
- Rituximabn = 5
- Tocilizumabn = 8
- Anti-TNFn = 4
- Outcome
- Joint response to targeted therapies by EULAR criteria based on DAS28
Methodological detailstwo academic centres, 10-year period, routine practice
- Two academic centres
- 10-year period
- Routine practice
Main finding
As reported in the abstract
EULAR "good" or "moderate" response
Observational data: associations, not effects.
Further findings
| Outcome | Difference | P value |
|---|---|---|
| Change in DAS28, T and B lymphocyte-targeted therapies vs cytokine inhibitors · 6 months | −1.75 | P = 0.016 |
GC consumption
- Trend to lower GC consumption with T and B lymphocyte-targeted therapies
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases. Clin Exp Rheumatol. Published 21 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →